Introduction/Background PARP inhibitors (PARPi) maintenance after Platinum (Pt) based chemotherapy (CT) significantly improves progression-free survival (PARPi-PFS) and PFS after subsequent (ssq) CT (PARPi-PFS2) in relapsed high grade serous ovarian cancer (HGSOC). Data regarding ssq CT is scarce, and PARPi/Pt crossed mechanisms of resistance may impact on outcome of ssq Pt. We provide Real-world-data on this issue.

Methodology We included HGSOC patients treated with ssq CT after progression to maintenance PARPi until 15th Jul 2020 in 3 hospitals. Endpoints were related to this ssq CT: objective response rate (ORR), median (m) progression-free survival (PFS) and overall survival (OS). Multivariate Cox and logistic regression models were adjusted by BRCA status and Pt-free interval (PFI) (6–12 months (mo) vs >12 mo). Adjusted hazard ratios (aHR) and odds ratios (aOR) of the risk of progression/death and ORR, respectively, were reported with 95% confidence intervals (CI).

Results 56 patients were identified (32 BRCAmut; 1 BRIP1mut). 4 patients (7.1%) received PARPi after 1st line CT, 26 (46.4%) after 2nd line and 26 (46.4%) after >3rd line. 34 patients (60.7%) received olaparib and 22 (39.3%) niraparib. m-PARPi-PFS in the recurrent setting was 7.5 mo (longer in BRCAmut: 10.1 vs 5.5 mo, p 0.03). m-PARPi-PFS2 was 15.8 mo (longer in BRCAmut: 20.9 vs 15.4 mo, p 0.07).

Endpoints regarding ssq CT are shown in table 1. ORR to ssq Pt was 33.3% and progression disease without any response 28.6%. ORR in patients who received ssq Pt-free CT, ssq Pt with PFI 6–12 mo, and ssq Pt with PFI >12 mo were 33.3%, 23.8% and 42.8%, respectively. Five complete responses occurred among BRCAmut patients that had received PARPi in the recurrent setting. mPFS and mOS were significantly longer in the PFI >12 subgroup vs the others (figure 1).

Focusing in patients receiving ssq Pt, when adjusting by BRCA status: aOR of ORR in patients with PFI >12 vs 6–12 mo was 0.56 (95% CI: 0.13 – 2.30), aHR of mPFS between these two subgroups was 0.61 (95% CI: 0.30–1.20; p 0.16), and aHR of mOS was 0.20 (95% CI: 0.7–0.61; p 0.005). Results did not change when excluding the 4 patients who received PARPi as 1st line.

Conclusion A trend towards higher benefit from ssq Pt after PARPi was observed in the PFI >12 subgroup. Benefit from ssq Pt after PARPi in the PFI 6–12 subgroup was similar to benefit from CT in the non-Pt subgroup. The role of ssq Pt after PARPi in the PFI 6–12 subgroup warrants further research.

Disclosures Andrea Plaja: travel grant for attending scientific meeting (Roche, Angelini).

Marta Gil-Marin: speaking (Roche, Astra Zeneca, Phamar) and travel grants (Roche, Pharmamar, MSD).

Beatriz Pardo: speaking (Roche, Astra Zeneca, MSD) and travel grants (Roche, MSD, GSK).

Josep Maria Piulats: advisory board (Astra Zeneca, MSD, Clovis, Beigene) and travel grants (Astra Zeneca, MSD, Beigene).

María Pilar Barretina: advisory board (Roche, Astra Zeneca, GSK, Clovis Oncology), speaking (Roche, Astra Zeneca, GSK, Clovis Oncology, Pharmamar) and travel grants (Roche, GSK, Astra Zeneca, Pharmamar).

Claudia Fina: travel grants (Roche, MSD, Pfizer, Bristol-Myers).

Margarita Romeo: advisory boards (AZ, TESARO) and travel grants (Pfizer).

Iris Teruel, Anna Esteve and Andrea Gonzalez have nothing to disclose.

Abstract 281 Table 1 Endpoints regarding ssq CT

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Non Pt-CT</th>
<th>Pt-CT</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BRCAmut/BRIP1mut (n, %)</td>
<td>5 (9.1%)</td>
<td>1 (1.9%)</td>
<td></td>
</tr>
<tr>
<td>PFI 6–12 mo</td>
<td>11 (20.0%)</td>
<td>24 (44.0%)</td>
<td></td>
</tr>
<tr>
<td>PFI &gt;12 mo</td>
<td>21 (38.0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Best responses (n, %)*

<table>
<thead>
<tr>
<th>Response</th>
<th>Non Pt-CT</th>
<th>Pt-CT</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>2 (3.6%)</td>
<td>0 (0.0%)</td>
<td>0.031</td>
</tr>
<tr>
<td>Partial response</td>
<td>2 (3.6%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>Stable disease</td>
<td>2 (3.6%)</td>
<td>0 (0.0%)</td>
<td></td>
</tr>
<tr>
<td>Progression disease</td>
<td>4 (6.8%)</td>
<td>10 (18.2%)</td>
<td>0.031</td>
</tr>
<tr>
<td>mPFS (mo, 95%CI)</td>
<td>5.1 (2.7)</td>
<td>5.5 (3.9–6.9)</td>
<td>0.055</td>
</tr>
<tr>
<td>mOS (mo, 95%CI)</td>
<td>6.8 (4.6)</td>
<td>14.2 (9.4–21.9)</td>
<td>0.018</td>
</tr>
</tbody>
</table>

*Evaluable patients (n=51)

Focusing in patients receiving ssq Pt, when adjusting by BRCA status: aOR of ORR in patients with PFI >12 vs 6–12 mo was 0.56 (95% CI: 0.13 – 2.30), aHR of mPFS between these two subgroups was 0.61 (95% CI: 0.30–1.20; p 0.16), and aHR of mOS was 0.20 (95% CI: 0.7–0.61; p 0.005). Results did not change when excluding the 4 patients who received PARPi as 1st line.

Conclusion A trend towards higher benefit from ssq Pt after PARPi was observed in the PFI >12 subgroup. Benefit from ssq Pt after PARPi in the PFI 6–12 subgroup was similar to benefit from CT in the non-Pt subgroup. The role of ssq Pt after PARPi in the PFI 6–12 subgroup warrants further research.

Disclosures Andrea Plaja: travel grant for attending scientific meeting (Roche, Angelini).

Marta Gil-Marin: speaking (Roche, Astra Zeneca, Phamar) and travel grants (Roche, Pharmamar, MSD).

Beatriz Pardo: speaking (Roche, Astra Zeneca, MSD) and travel grants (Roche, MSD, GSK).

Josep Maria Piulats: advisory board (Astra Zeneca, MSD, Clovis, Beigene) and travel grants (Astra Zeneca, MSD, Beigene).

María Pilar Barretina: advisory board (Roche, Astra Zeneca, GSK, Clovis Oncology), speaking (Roche, Astra Zeneca, GSK, Clovis Oncology, Pharmamar) and travel grants (Roche, GSK, Astra Zeneca, Pharmamar).

Claudia Fina: travel grants (Roche, MSD, Pfizer, Bristol-Myers).

Margarita Romeo: advisory boards (AZ, TESARO) and travel grants (Pfizer).

Iris Teruel, Anna Esteve and Andrea Gonzalez have nothing to disclose.
Abstracts

Introduction/Background Malignant sex cord stroma cell tumours (SCST) account for less than eight percent of ovarian malignancies. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) has established a clinicopathological (Current Ovarian geRm cell and SEx cord stromal Tumour Treatment strategies, CORSETT) database for a better documentation and understanding of this rare disease. Here, we present the first clinicopathological descriptive analysis for patients with independently confirmed SCST from the CORSETT database.

Methodology 20 German centres entered mixed retro- and prospective data of SCST patients with tumour specimens available treated between 2000 to 2014 into the CORSETT database. An independent CORSETT pathology reference panel checked the primary histological diagnosis. We conducted a descriptive analysis of the treatment strategies and created Kaplan-Meier curves and cox regression analyses for the survival analysis.

Results The reference pathology panel diagnosed 143 patients with granulosa cell (GCT, FIGO stage I=120, 87.0%) and 14 patients with Sertoli-Leydig cell (SLCT, FIGO stage I = 11, 91.7%) tumours (others = 5). The median age of patients with GCT was 57.6 years (SLCT: 47.2 years). 87 of GCT (61.7%) and eight SLCT (57.1%) patients were treated with laparoscopy and the tumour ruptured intraoperatively in 22% (SLCT: 7.7%) of the cases. 57 GCT (45%) and eight SLCT (57%) patients received fertility-sparing surgery. 19 of GCT (15%) and two SLCT (15.4%) patients received adjuvant chemotherapy. 59 of GCT (45%) and two of SLCT (14.3%) patients experienced a disease recurrence. The median progression-free survival (PFS) for all SCST patients was 80.4 months, (overall survival not reached). Advanced FIGO stage was associated with decreased PFS (p < 0.05). Adjuvant chemotherapy had no statistically significant beneficial effect on PFS (all regimens p > 0.05).

Conclusion In this analysis, almost every fourth SCST patient treated surgically experienced an intraoperative cyst rupture that had however no impact on disease recurrence. One in five SCST patient received adjuvant chemotherapy that had no PFS improvement.

Disclosures

290 TARGETING AKT AND DNA-PK AS A THERAPEUTIC STRATEGY IN PLATINUM RESISTANT HIGH-GRADE SEROUS OVARIAN CANCER

1Natasha Rinne, 1Shengnan Yuan, 1Christina Fotopoulou, 2Hani Gabra, 1Paula Cunnea. 1Imperial College London; Division of Cancer, Department of Surgery and Cancer; 2Bergenbio, Magdalen Centre; Robert Robinson Avenue, The Oxford Science Park 10.1136/ijgc-2020-ESGO.112

Introduction/Background High-grade serous ovarian cancer (HGSOC) is the most lethal form of gynaecological malignancy. Despite initial sensitivity to platinum chemotherapy, the majority of patients develop resistance to treatment and eventually die. Current treatment options for platinum-resistant patients are limited.

The role of the PI3K/AKT/mTOR pathway has been described in chemo-resistant HGSOC, in particular through activation of AKT by DNA-PK in response to platinum treatment. As increasing numbers of AKT and DNA-PK inhibitors advance to clinical trials, determining mechanism of action and efficacy is crucial.

This project aims to evaluate inhibition of AKT or DNA-PK as a therapeutic strategy to target platinum resistance in HGSOC, and identify proteomic signatures confirming mechanism of action and target inhibition.

Methodology A panel of seven AKT and DNA-PK inhibitors were tested in combination with cisplatin chemotherapy in immortalised HGSOC cell lines and primary tumour cells cultured from HGSOC tumour/ascites samples. Clonogenic assays were performed to establish effect of inhibitor treatment in combination with cisplatin chemotherapy on the ability of cells to form colonies. Isobologram assays were performed to establish synergy/antagonism between inhibitors and cisplatin chemotherapy. Proteomic Reverse Phase Protein Array (RPPA) was performed to determine the mechanism of action of inhibitors, and results were confirmed with immunoblotting.

Results Treatment with AKT or DNA-PK inhibitors in combination with cisplatin led to significantly enhanced apoptotic responses in immortalised platinum-resistant HGSOC cell lines (n=5), and in primary cells derived from ascites or tumour (n=4, p<0.01, p<0.05), compared to cisplatin treatment alone. In platinum-resistant HGSOC cell lines, fewer cell colonies were observed with increasing concentrations of AKT or DNA-PK inhibitors in combination with cisplatin (n=3) in comparison with cisplatin alone. Varying synergistic effects were observed across the panel of inhibitors when combined with cisplatin; Uprosertib (AKT inhibitor) in particular displayed strong synergy with cisplatin (Loewe analysis). Proteomic analysis of inhibitor treatment in HGSOC platinum-resistant cells demonstrated the mechanism of action of Uprosertib in targeting the PI3K/AKT pathway.

Conclusion In platinum-resistant HGSOC cells, AKT or DNA-PK inhibition functioned synergistically with cisplatin and reduced cell growth and proliferation. In both immortalised and primary HGSOC cell lines tested, AKT or DNA-PK inhibition significantly enhanced the apoptotic response to cisplatin demonstrating the efficacy of AKT or DNA-PK as potential therapeutic targets in chemoresistant HGSOC. By improving patient response to treatment, AKT and DNA-PK inhibitors could expand the therapeutic options for patients with platinum-resistant HGSOC, improving overall survival.

Disclosures CF: advisory boards and honoraria from Roche, Tesaro, Sequana, Olympus, Astra Zeneca. Other authors have no conflict of interest.

293 TREATMENT STRATEGIES AND SURVIVAL OF WOMEN WITH MALIGNANT OVARIAN GERM CELL TUMOURS – AN ANALYSIS OF THE AGO-CORSETT DATABASE

1Annette Hasenburg, 2Helmut Plett, 3Philipp Harter, 4Stefan Kommoss, 5Jacqueline Keul, 6Eva Röser, 7Bastian Czogalla, 8Michaela Bossart, 9Theresa Link, 10Maximilian Klar. 1Dept Gynakologie und Geburtshilfe; University Hospital Tuebingen; 2Dept Gynakologie und Geburtshilfe; University Hospital Tuebingen; 3Klinikum Steckhardt, Klinikum der Universität München; 4University Hospital Tuebingen; 5Klinikum der Universität München; 6University Hospital Tuebingen; 7Universitätsfrauenklinik, University Hospital Tuebingen; 8Universitätsfrauenklinik, University Hospital Tuebingen; 9University Hospital Tuebingen; 10University Hospital Tuebingen 10.1136/ijgc-2020-ESGO.113

Introduction/Background Malignant ovarian germ cell tumours (OGCT) account for about five percent of all ovarian malignancies in Western countries. The Arbeitsgemeinschaft fuer